Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FDYIA
ADC Name
WO2020063676A1 ADC-21
Synonyms
WO2020063676A1_ADC 21
   Click to Show/Hide
Organization
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
7.23
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2020063676A1_ADC-21 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 15.01
%
SK-BR-3 cells
Breast adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 46.22
%
JIMT-1 cells
Breast ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 56.77
%
JIMT-1 cells
Breast ductal carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 77.4
%
SK-BR-3 cells
Breast adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 4 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 15.01% (Day 28) Positive HER2 expression (HER2 +++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 1 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model SK-BR-3 CDX model
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 46.22% (Day 34) Positive HER2 expression (HER2 +++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model JIMT-1 CDX model
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 56.77% (Day 34) Positive HER2 expression (HER2 +++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.p.*2 of one of the conjugates listed above or with PBS only.
In Vivo Model JIMT-1 CDX model
In Vitro Model Breast ductal carcinoma JIMT-1 cells CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 77.40% (Day 28) Positive HER2 expression (HER2 +++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 6 mg/kg, i.p.ONCE of one of the conjugates listed above or with PBS only.
In Vivo Model SK-BR-3 CDX model
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
References
Ref 1 Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof; 2020-04-02.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.